Positron Emission Tomography of Brain β-Amyloid and Tau Levels in Adults With Down Syndrome
Authors:
- 1 June 2011
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 68 (6) , 768-774
Abstract
Objectives: To determine the neuropathological load in the living brain of nondemented adults with Down syndrome using positron emission tomography with 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl) methylamino]2- napthyl} ethylidene) malononitrile ([(18)F] FDDNP) and to assess the influence of age and cognitive and behavioral functioning. For reference, [(18)F] FDDNP binding values and patterns were compared with those from patients with Alzheimer disease and cognitively intact control participants. Design: Cross-sectional clinical study. Participants: Volunteer sample of 19 persons with Down syndrome without dementia (mean age, 36.7 years), 10 patients with Alzheimer disease (mean age, 66.5 years), and 10 controls (mean age, 43.8 years). Main Outcome Measures: Binding of [(18)F] FDDNP in brain regions of interest, including the parietal, medial temporal, lateral temporal, and frontal lobes and posterior cingulate gyrus, and the average of all regions (global Results: The [(18)F] FDDNP binding values were higher in all brain regions in the Down syndrome group than in controls. Compared with the Alzheimer disease group, the Down syndrome group had higher [(18)F] FDDNP binding values in the parietal and frontal regions, whereas binding levels in other regions were comparable. Within the Down syndrome group, age correlated with [(18)F] FDDNP binding values in all regions except the posterior cingulate, and several measures of behavioral dysfunction showed positive correlations with global, frontal, parietal, and posterior cingulate [(18)F] FDDNP binding. Conclusions: Consistent with neuropathological findings from postmortem studies, [(18)F] FDDNP positron emission tomography shows high binding levels in Down syndrome comparable to Alzheimer disease and greater levels than in members of a control group. The positive associations between [(18)F] FDDNP binding levels and age as well as behavioral dysfunction in Down syndrome are consistent with the age-related progression of Alzheimer-type neuropathological findings in this population.Keywords
This publication has 49 references indexed in Scilit:
- Neuropathologic Features of Amnestic Mild Cognitive ImpairmentArchives of Neurology, 2006
- The 2,6‐Disubstituted Naphthalene Derivative FDDNP Labeling Reliably Predicts Congo Red Birefringence of Protein Deposits in Brain Sections of Selected Human Neurodegenerative DiseasesBrain Pathology, 2006
- Amyloidogenic processing of β-amyloid precursor protein in intracellular compartmentsNeurology, 2006
- Learning and memory as a function of age in Down syndrome: A study using animal-based tasksProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2005
- Regional brain function, emotion and disorders of emotionCurrent Opinion in Neurobiology, 1999
- Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative AnalysisExperimental Neurology, 1998
- Age-Related Distribution of Neuropathologic Changes in the Cerebral Cortex of Patients With Down's SyndromeArchives of Neurology, 1995
- Emotional sequelae of stroke: A longitudinal perspectiveJournal of Clinical and Experimental Neuropsychology, 1994
- Nature of mental retardation and dementia in down syndrome: Study with PET, CT, and neuropsychologyNeurobiology of Aging, 1992
- Evaluation of a screening instrument for dementia in ageing mentally retarded personsJournal of Intellectual Disability Research, 1992